Roivant Sciences (ROIV) Other Non-Current Assets (2021 - 2026)
Roivant Sciences (ROIV) posted Other Non-Current Assets of $40.9 million for Q1 2026, up 18.38% on a QoQ basis from $34.6 million in Q4 2025, and up 24.52% year-over-year from $32.9 million in Q1 2025.
Roivant Sciences (ROIV) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Roivant Sciences' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $40.9 million for Q1 2026.
- Quarterly Other Non-Current Assets rose 24.52% year-over-year to $40.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.9 million (up 24.52% YoY) and the FY2026 annual result came in at $40.9 million, up 24.52% from the prior year.
- Other Non-Current Assets was $40.9 million for Q1 2026 at Roivant Sciences, up from $34.6 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $145.9 million in Q1 2024 and bottomed at $11.9 million in Q3 2022.
- A 5-year average of $41.6 million and a median of $34.6 million in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 417.27% — and 2025, when it tumbled 77.47%.
- Roivant Sciences' Other Non-Current Assets stood at $46.2 million in 2022, then rose by 1.35% to $46.8 million in 2023, then slipped by 27.68% to $33.9 million in 2024, then grew by 2.02% to $34.6 million in 2025, then gained by 18.38% to $40.9 million in 2026.
- Business Quant data shows ROIV's Other Non-Current Assets at $40.9 million in Q1 2026, $34.6 million in Q4 2025, and $27.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | 40.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.92 Mn |
| Dec 31, 2025 | 34.56 Mn |
| Sep 30, 2025 | 27.83 Mn |
| Jun 30, 2025 | 31.09 Mn |
| Mar 31, 2025 | 32.86 Mn |
| Dec 31, 2024 | 33.88 Mn |
| Sep 30, 2024 | 36.90 Mn |
| Jun 30, 2024 | 32.81 Mn |
| Mar 31, 2024 | 145.88 Mn |
| Dec 31, 2023 | 46.85 Mn |
| Sep 30, 2023 | 49.80 Mn |
| Jun 30, 2023 | 46.31 Mn |
| Mar 31, 2023 | 49.48 Mn |
| Dec 31, 2022 | 46.22 Mn |
| Sep 30, 2022 | 11.87 Mn |
| Jun 30, 2022 | 14.25 Mn |
| Mar 31, 2022 | 25.82 Mn |
| Dec 31, 2021 | 8.94 Mn |
| Sep 30, 2021 | 21.34 Mn |
| Jun 30, 2021 | 8.93 Mn |